Point-of-care (POC) molecular diagnostics are tests designed to detect specific nucleic acids in clinical specimens, including feces, saliva, urine, blood, and tissue. These diagnostics rely on identifying targeted portions of microbial genetic material, specifically DNA or RNA. Widely utilized in the healthcare sector, POC molecular diagnostics are granted emergency usage authorization to diagnose various diseases. These diagnostics are instrumental in detecting disease antigens or antibodies in human samples, such as mononucleosis, influenza, and group A streptococcus (GAS).
The primary products and services in point-of-care molecular diagnostics include assays and kits, instruments and analyzers, and software and services. Assays and kits are equipment used to carry out analyses, especially in studying disease pathways. They are commonly employed for rapid and accurate diagnosis and monitoring of various diseases. Technologies such as reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, and sequencing are utilized in POC molecular diagnostics for diagnosing diseases like respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis, and hematology. Point-of-care molecular diagnostics are employed in decentralized labs, hospitals, home care, and assisted living healthcare facilities.
The point-of-care molecular diagnostics market research report is one of a series of new reports that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The point-of-care molecular diagnostics market size has grown rapidly in recent years. It will grow from $3.21 billion in 2023 to $3.64 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The growth observed in the historical period can be attributed to the increasing demand for rapid disease diagnosis, the growth in infectious disease outbreaks, the expansion of telemedicine and remote testing, regulatory support for point-of-care diagnostics, and the need for personalized and precision medicine.
The point-of-care molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $6.15 billion in 2028 at a compound annual growth rate (CAGR) of 14.0%. The anticipated growth in the forecast period can be attributed to the miniaturization of diagnostic devices, the expansion of point-of-care testing for cancer and genetic diseases, the development of customized molecular diagnostics for diverse applications, the integration of AI and machine learning for data analysis, and the emergence of infectious disease surveillance. Noteworthy trends expected in the forecast period encompass the adoption of lab-on-a-chip and microfluidic technologies, the advancement of digital health and smartphone-based diagnostics, the prominence of point-of-care COVID-19 and pandemic preparedness, the implementation of AI-driven predictive diagnostics, and the utilization of CRISPR-based molecular testing.
The significant rise in the prevalence of infectious and respiratory diseases is anticipated to be a major driver for the growth of the point-of-care molecular diagnostics market. Microorganisms causing respiratory infections, whether viral or bacterial, can spread through various means, including coughing, sneezing, or direct contact. The severity of these diseases necessitates a range of treatments, including inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostics for effective patient care. For example, in England, according to the Office for National Statistics, the infection rate increased among individuals aged 35 to 69 and those in school years 12 to 24, highlighting the urgency for effective point-of-care molecular diagnostics to address infectious and respiratory diseases.
The increasing awareness regarding heart failure treatment is poised to propel the growth of the point-of-care (POC) molecular diagnostics market. Heart failure, a condition impacting the heart's ability to pump blood effectively, can benefit significantly from POC molecular diagnostics, offering swift and accurate diagnoses for early interventions and improved patient outcomes. The American Heart Association reports a rising number of heart failure diagnoses, projected to increase by 46% by 2030, exceeding 8 million people with heart failure. In India, coronary incidences have surged in both rural and urban populations. This growing awareness about heart failure treatment underscores the potential for POC molecular diagnostics to play a crucial role in this medical domain.
A key trend gaining traction in the point-of-care molecular diagnostics market is technological innovation. Major market players are dedicated to providing advanced solutions to strengthen their market positions. Companies are incorporating next-generation technologies such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, etc., on POC devices, accelerating analysis times and reducing costs. For instance, Sensible Diagnostics introduced a 10-minute point-of-care PCR system, showcasing technological advancements to provide rapid results.
Strategic partnerships are being embraced by major players in the point-of-care molecular diagnostics market to launch POC CRISPR-based tests. For instance, CrisprBits collaborated with MolBio Diagnostics to leverage biotechnology expertise and translation, manufacturing, and distribution capabilities for developing POC tests detecting pathogens and genetic markers.
In February 2021, Thermo Fisher Scientific made a significant move by acquiring Mesa Biotech, a point-of-care molecular diagnostics company. This acquisition allows Thermo Fisher Scientific to expand its presence in point-of-care molecular diagnostics, addressing the demand for diagnostics on a larger scale.
Major companies operating in the point-of-care molecular diagnostics market include Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMérieux SA, Danaher Corporation, Quidel Corporation, BioMerieux SA, Bio-Rad Laboratories Inc., Sysmex Corporation, Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Biogenex Laboratories Inc., Cepheid Inc., Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Prometheus Laboratories Inc., Ventana Medical Systems Inc., Vermillion Inc., Guardant Health Inc., Exact Sciences Corporation, Biocartis Group NV, ArcherDx Inc., Bio-Techne Corporation, AccuBiotech Co. Ltd., Becton, Dickinson and Company, Chembio Diagnostics Inc., Credo Diagnostics Biomedical Pvt. Ltd., EKF Diagnostics, GenePOC Inc.
North America was the largest region in the point-of-care molecular diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The primary products and services in point-of-care molecular diagnostics include assays and kits, instruments and analyzers, and software and services. Assays and kits are equipment used to carry out analyses, especially in studying disease pathways. They are commonly employed for rapid and accurate diagnosis and monitoring of various diseases. Technologies such as reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, and sequencing are utilized in POC molecular diagnostics for diagnosing diseases like respiratory diseases, hospital-acquired infections (HAIs), cancer/oncology, hepatitis, and hematology. Point-of-care molecular diagnostics are employed in decentralized labs, hospitals, home care, and assisted living healthcare facilities.
The point-of-care molecular diagnostics market research report is one of a series of new reports that provides point-of-care molecular diagnostics market statistics, including point-of-care molecular diagnostics industry global market size, regional shares, competitors with a point-of-care molecular diagnostics market share, detailed point-of-care molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care molecular diagnostics industry. This point-of-care molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The point-of-care molecular diagnostics market size has grown rapidly in recent years. It will grow from $3.21 billion in 2023 to $3.64 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The growth observed in the historical period can be attributed to the increasing demand for rapid disease diagnosis, the growth in infectious disease outbreaks, the expansion of telemedicine and remote testing, regulatory support for point-of-care diagnostics, and the need for personalized and precision medicine.
The point-of-care molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $6.15 billion in 2028 at a compound annual growth rate (CAGR) of 14.0%. The anticipated growth in the forecast period can be attributed to the miniaturization of diagnostic devices, the expansion of point-of-care testing for cancer and genetic diseases, the development of customized molecular diagnostics for diverse applications, the integration of AI and machine learning for data analysis, and the emergence of infectious disease surveillance. Noteworthy trends expected in the forecast period encompass the adoption of lab-on-a-chip and microfluidic technologies, the advancement of digital health and smartphone-based diagnostics, the prominence of point-of-care COVID-19 and pandemic preparedness, the implementation of AI-driven predictive diagnostics, and the utilization of CRISPR-based molecular testing.
The significant rise in the prevalence of infectious and respiratory diseases is anticipated to be a major driver for the growth of the point-of-care molecular diagnostics market. Microorganisms causing respiratory infections, whether viral or bacterial, can spread through various means, including coughing, sneezing, or direct contact. The severity of these diseases necessitates a range of treatments, including inhalers, oral medications, intravenous treatments, and point-of-care molecular diagnostics for effective patient care. For example, in England, according to the Office for National Statistics, the infection rate increased among individuals aged 35 to 69 and those in school years 12 to 24, highlighting the urgency for effective point-of-care molecular diagnostics to address infectious and respiratory diseases.
The increasing awareness regarding heart failure treatment is poised to propel the growth of the point-of-care (POC) molecular diagnostics market. Heart failure, a condition impacting the heart's ability to pump blood effectively, can benefit significantly from POC molecular diagnostics, offering swift and accurate diagnoses for early interventions and improved patient outcomes. The American Heart Association reports a rising number of heart failure diagnoses, projected to increase by 46% by 2030, exceeding 8 million people with heart failure. In India, coronary incidences have surged in both rural and urban populations. This growing awareness about heart failure treatment underscores the potential for POC molecular diagnostics to play a crucial role in this medical domain.
A key trend gaining traction in the point-of-care molecular diagnostics market is technological innovation. Major market players are dedicated to providing advanced solutions to strengthen their market positions. Companies are incorporating next-generation technologies such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), mass spectrometry (MS), situ hybridizations, spectral karyotyping imaging, DNA microarrays, etc., on POC devices, accelerating analysis times and reducing costs. For instance, Sensible Diagnostics introduced a 10-minute point-of-care PCR system, showcasing technological advancements to provide rapid results.
Strategic partnerships are being embraced by major players in the point-of-care molecular diagnostics market to launch POC CRISPR-based tests. For instance, CrisprBits collaborated with MolBio Diagnostics to leverage biotechnology expertise and translation, manufacturing, and distribution capabilities for developing POC tests detecting pathogens and genetic markers.
In February 2021, Thermo Fisher Scientific made a significant move by acquiring Mesa Biotech, a point-of-care molecular diagnostics company. This acquisition allows Thermo Fisher Scientific to expand its presence in point-of-care molecular diagnostics, addressing the demand for diagnostics on a larger scale.
Major companies operating in the point-of-care molecular diagnostics market include Abbott Laboratories, F Hoffmann-La Roche Ltd., BioMérieux SA, Danaher Corporation, Quidel Corporation, BioMerieux SA, Bio-Rad Laboratories Inc., Sysmex Corporation, Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Biogenex Laboratories Inc., Cepheid Inc., Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Prometheus Laboratories Inc., Ventana Medical Systems Inc., Vermillion Inc., Guardant Health Inc., Exact Sciences Corporation, Biocartis Group NV, ArcherDx Inc., Bio-Techne Corporation, AccuBiotech Co. Ltd., Becton, Dickinson and Company, Chembio Diagnostics Inc., Credo Diagnostics Biomedical Pvt. Ltd., EKF Diagnostics, GenePOC Inc.
North America was the largest region in the point-of-care molecular diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care molecular diagnostics market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the point-of-care molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The point-of-care (POC) molecular diagnostics market includes revenues earned by AAT, antigen, or antibody tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Point-Of-Care Molecular Diagnostics Market Characteristics3. Point-Of-Care Molecular Diagnostics Market Trends And Strategies31. Global Point-Of-Care Molecular Diagnostics Market Competitive Benchmarking32. Global Point-Of-Care Molecular Diagnostics Market Competitive Dashboard33. Key Mergers And Acquisitions In The Point-Of-Care Molecular Diagnostics Market
4. Point-Of-Care Molecular Diagnostics Market - Macro Economic Scenario
5. Global Point-Of-Care Molecular Diagnostics Market Size and Growth
6. Point-Of-Care Molecular Diagnostics Market Segmentation
7. Point-Of-Care Molecular Diagnostics Market Regional And Country Analysis
8. Asia-Pacific Point-Of-Care Molecular Diagnostics Market
9. China Point-Of-Care Molecular Diagnostics Market
10. India Point-Of-Care Molecular Diagnostics Market
11. Japan Point-Of-Care Molecular Diagnostics Market
12. Australia Point-Of-Care Molecular Diagnostics Market
13. Indonesia Point-Of-Care Molecular Diagnostics Market
14. South Korea Point-Of-Care Molecular Diagnostics Market
15. Western Europe Point-Of-Care Molecular Diagnostics Market
16. UK Point-Of-Care Molecular Diagnostics Market
17. Germany Point-Of-Care Molecular Diagnostics Market
18. France Point-Of-Care Molecular Diagnostics Market
19. Italy Point-Of-Care Molecular Diagnostics Market
20. Spain Point-Of-Care Molecular Diagnostics Market
21. Eastern Europe Point-Of-Care Molecular Diagnostics Market
22. Russia Point-Of-Care Molecular Diagnostics Market
23. North America Point-Of-Care Molecular Diagnostics Market
24. USA Point-Of-Care Molecular Diagnostics Market
25. Canada Point-Of-Care Molecular Diagnostics Market
26. South America Point-Of-Care Molecular Diagnostics Market
27. Brazil Point-Of-Care Molecular Diagnostics Market
28. Middle East Point-Of-Care Molecular Diagnostics Market
29. Africa Point-Of-Care Molecular Diagnostics Market
30. Point-Of-Care Molecular Diagnostics Market Competitive Landscape And Company Profiles
34. Point-Of-Care Molecular Diagnostics Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
Point-Of-Care Molecular Diagnostics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on point-of-care molecular diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- All data from the report will also be delivered in an excel dashboard format.
Description:
Where is the largest and fastest growing market for point-of-care molecular diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
- Markets Covered: 1) By Product And Service: Assays And Kits; Instruments And Analyzers; Software And Services 2) By Technology: Reverse Transcription - Polymerase Chain Reaction (RT-PCR); In Situ Hybridization; Sequencing 3) By Application: Respiratory Diseases; Hospital Acquired Infections (HAIs); Cancer/Oncology; Hepatitis; Hematology 4) By End-User: Decentralized Labs; Hospitals; Home Care; Assisted Living Healthcare Facilities
- Companies Mentioned: Abbott Laboratories; F Hoffmann-La Roche Ltd.; BioMérieux SA; Danaher Corporation; Quidel Corporation
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- F Hoffmann-La Roche Ltd.
- BioMérieux SA
- Danaher Corporation
- Quidel Corporation
- BioMerieux SA
- Bio-Rad Laboratories Inc.
- Sysmex Corporation
- Illumina Inc.
- Myriad Genetics Inc.
- Siemens Healthcare GmbH
- Almac Group
- Biogenex Laboratories Inc.
- Cepheid Inc.
- Epic Sciences Inc.
- Foundation Medicine Inc.
- Genomic Health Inc.
- Grail Inc.
- Hologic Inc.
- HTG Molecular Diagnostics Inc.
- Inivata Ltd.
- Invivoscribe Inc.
- MolecularMD Corporation
- Natera Inc.
- NeoGenomics Laboratories Inc.
- Personal Genome Diagnostics Inc.
- Prometheus Laboratories Inc.
- Ventana Medical Systems Inc.
- Vermillion Inc.
- Guardant Health Inc.
- Exact Sciences Corporation
- Biocartis Group NV
- ArcherDx Inc.
- Bio-Techne Corporation
- AccuBiotech Co. Ltd.
- Becton, Dickinson and Company
- Chembio Diagnostics Inc.
- Credo Diagnostics Biomedical Pvt. Ltd.
- EKF Diagnostics
- GenePOC Inc.
Methodology
LOADING...
